Skip to main
DMRA

Galecto Inc (DMRA) Stock Forecast & Price Target

Galecto Inc (DMRA) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Damora Therapeutics is expected to see success with its pipeline products, notably DMR-001, due to the potential for higher pricing and a unique profile that may appeal to a broader patient population. The company also has a strong management team led by CEO Ms. Jarrett, which brings expertise and experience in the life sciences industry. The success of DMR-001 may also disrupt the market and compete with current standards of treatment, such as Incyte's JAK inhibitors, providing a potential area for growth in a crucial medical need for disease-modifying options.

Bears say

Damora Therapeutics is facing a difficult road ahead as they aim to revolutionize care for people with hematologic disorders through the development of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms. However, key factors such as target engagement, VAF reduction, and patient outcomes may not be reached in their Phase 3 initiation in 2028, and competition from incumbents and next-generation therapies could weaken their position. Despite their promising pipeline, early data and financial metrics suggest a challenging road to success, with the potential for disappointing POC readouts and cash burn in the coming years.

Galecto Inc (DMRA) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Galecto Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Galecto Inc (DMRA) Forecast

Analysts have given Galecto Inc (DMRA) a Buy based on their latest research and market trends.

According to 4 analysts, Galecto Inc (DMRA) has a Buy consensus rating as of Jun 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Galecto Inc (DMRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.